<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-11T12:59:15Z</responseDate>
  <request identifier="oai:figshare.com:article/33853396" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33853396</identifier>
        <datestamp>2026-09-16T13:56:11Z</datestamp>
        <setSpec>category_37</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Data Sheet 1_Identification of natural TLR4 modulators through network pharmacology and molecular modeling in SARS-CoV-2 Acinetobacter baumannii co-infection.docx</dc:title>
          <dc:creator>Mebarka Ouassaf (10715532)</dc:creator>
          <dc:creator>Shafi Ullah Khan (3771583)</dc:creator>
          <dc:creator>Kannan R. R. Rengasamy (9610349)</dc:creator>
          <dc:creator>Nada S. Alhaggass (24985999)</dc:creator>
          <dc:creator>Bader Y. Alhatlani (12506090)</dc:creator>
          <dc:subject>Organic Chemistry</dc:subject>
          <dc:subject>Acinetobacter baumannii</dc:subject>
          <dc:subject>admet</dc:subject>
          <dc:subject>co-infection</dc:subject>
          <dc:subject>host-directed therapy</dc:subject>
          <dc:subject>molecular docking</dc:subject>
          <dc:subject>molecular dynamics</dc:subject>
          <dc:subject>natural compounds</dc:subject>
          <dc:subject>network pharmacology</dc:subject>
          <dc:description>&lt;p&gt;Viral–bacterial co-infection with SARS-CoV-2 and Acinetobacter baumannii exacerbates hyperinflammation via Toll-like receptor 4 (TLR4)-mediated immune pathways. Using network pharmacology, an integrated protein–protein interaction network identified 30 key inter-species hubs comprising viral, bacterial, and human host proteins, with TLR4 achieving a high MCC score (722), highlighting its high topological centrality as a host immune target. Virtual screen of 2,820 natural compounds against the TLR4/MD-2 complex identified three top candidates, CID5898023, CID5403474, and CID74977829, with docking scores of −10.46, −10.02, and −9.58 kcal/mol, respectively, compared with −9.10 kcal/mol for the reference antagonist Eritoran. CID5898023 (curcumin-derived) exhibited a more favorable docking score and stable binding behavior during the molecular dynamics simulation compared with the reference antagonist Eritoran. CID74977829 (baicalin-derived) showed stable binding but lower intestinal absorption, while CID5403474 (chrysin-derived) lacked conformational stability despite favorable docking scores. These computational findings prioritize curcumin- and baicalin-derived scaffolds as potential TLR4/MD-2 modulators for further experimental investigation in the context of co-infection-associated inflammation.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-16T13:56:11Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fchem.2026.1916568.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Data_Sheet_1_Identification_of_natural_TLR4_modulators_through_network_pharmacology_and_molecular_modeling_in_SARS-CoV-2_Acinetobacter_baumannii_co-infection_docx/33853396</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
